Literature DB >> 1502878

Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins.

T Yamada1, P L McGeer, E G McGeer.   

Abstract

The substantia nigra (SN) in 11 Parkinson's disease (PD) patients and 5 neurologically normal controls was examined immunohistochemically using antibodies to various proteins of the complement system. In PD, but not in control SN, intra- and extraneuronal Lewy bodies and dendritic spheroid bodies were stained with anti-human C3d, C4d, C7 and C9 antibodies, but not with antibodies to C1q, fraction Bb of factor B or properdin. Axonal spheroid bodies in the nigrostriatal tract were not stained by any of the complement antibodies. However, complement-activated oligodendroglia were revealed by anti-C3d and anti-C4d antibodies in the PD substantia nigral area. These data indicate that some pathological structures in PD activate the classical complement pathway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1502878     DOI: 10.1007/bf00427222

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments.

Authors:  M A Pappolla
Journal:  Arch Pathol Lab Med       Date:  1986-12       Impact factor: 5.534

2.  Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d.

Authors:  T Yamada; H Akiyama; P L McGeer
Journal:  Neurosci Lett       Date:  1990-05-04       Impact factor: 3.046

Review 3.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K.

Authors:  T Yamada; P L McGeer; K G Baimbridge; E G McGeer
Journal:  Brain Res       Date:  1990-09-03       Impact factor: 3.252

5.  Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases.

Authors:  J Lowe; H McDermott; M Landon; R J Mayer; K D Wilkinson
Journal:  J Pathol       Date:  1990-06       Impact factor: 7.996

6.  New aspects of the pathology of neurodegenerative disorders as revealed by ubiquitin antibodies.

Authors:  P N Leigh; A Probst; G E Dale; D P Power; J P Brion; A Dodson; B H Anderton
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Rate of cell death in parkinsonism indicates active neuropathological process.

Authors:  P L McGeer; S Itagaki; H Akiyama; E G McGeer
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

8.  Two types of spheroid bodies in the nigral neurons in Parkinson's disease.

Authors:  T Yamada; H Akiyama; P L McGeer
Journal:  Can J Neurol Sci       Date:  1991-08       Impact factor: 2.104

9.  Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles.

Authors:  P G Galloway; I Grundke-Iqbal; K Iqbal; G Perry
Journal:  J Neuropathol Exp Neurol       Date:  1988-11       Impact factor: 3.685

10.  Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies.

Authors:  S Love; T Saitoh; S Quijada; G M Cole; R D Terry
Journal:  J Neuropathol Exp Neurol       Date:  1988-07       Impact factor: 3.685

View more
  62 in total

Review 1.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 2.  Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.

Authors:  Hironori Yokoyama; Hiroto Uchida; Hayato Kuroiwa; Jiro Kasahara; Tsutomu Araki
Journal:  Neurol Sci       Date:  2010-11-24       Impact factor: 3.307

3.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 4.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

5.  Global protein differential expression profiling of cerebrospinal fluid samples pooled from Chinese sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Qi Shi; Hui-Fang Zhang; Jin Zhang; Chan Tian; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2013-08-04       Impact factor: 5.590

Review 6.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

Review 7.  Immune activation in brain aging and neurodegeneration: too much or too little?

Authors:  Kurt M Lucin; Tony Wyss-Coray
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

8.  Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease.

Authors:  W Le; D Rowe; W Xie; I Ortiz; Y He; S H Appel
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

Review 9.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

10.  Innate immune network in the retina activated by optic nerve crush.

Authors:  Justin P Templeton; Natalie E Freeman; John M Nickerson; Monica M Jablonski; Tonia S Rex; Robert W Williams; Eldon E Geisert
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-09       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.